Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

766 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A. Goetz MP, et al. Among authors: toi m. J Clin Oncol. 2017 Nov 10;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2. J Clin Oncol. 2017. PMID: 28968163 Clinical Trial.
Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery.
Tominaga T, Koyama H, Toge T, Miura S, Sugimachi K, Yamaguchi S, Hirata K, Monden Y, Nomura Y, Toi M, Kimijima I, Noguchi S, Sonoo H, Asaishi K, Ikeda T, Morimoto T, Ota J, Ohashi Y, Abe O. Tominaga T, et al. Among authors: toi m. J Clin Oncol. 2003 Mar 15;21(6):991-8. doi: 10.1200/JCO.2003.06.014. J Clin Oncol. 2003. PMID: 12637462 Clinical Trial.
Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
Saeki T, Nomizu T, Toi M, Ito Y, Noguchi S, Kobayashi T, Asaga T, Minami H, Yamamoto N, Aogi K, Ikeda T, Ohashi Y, Sato W, Tsuruo T. Saeki T, et al. Among authors: toi m. J Clin Oncol. 2007 Feb 1;25(4):411-7. doi: 10.1200/JCO.2006.08.1646. Epub 2006 Dec 18. J Clin Oncol. 2007. PMID: 17179098 Clinical Trial.
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.
Toi M, Iwata H, Fujiwara Y, Ito Y, Nakamura S, Tokuda Y, Taguchi T, Rai Y, Aogi K, Arai T, Watanabe J, Wakamatsu T, Katsura K, Ellis CE, Gagnon RC, Allen KE, Sasaki Y, Takashima S. Toi M, et al. Br J Cancer. 2009 Nov 17;101(10):1676-82. doi: 10.1038/sj.bjc.6605343. Epub 2009 Oct 20. Br J Cancer. 2009. PMID: 19844234 Free PMC article. Clinical Trial.
Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
Toi M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Takada M, Ueno T, Saji S, Chanplakorn N, Suzuki T, Sasano H. Toi M, et al. Cancer Sci. 2011 Apr;102(4):858-65. doi: 10.1111/j.1349-7006.2011.01867.x. Epub 2011 Feb 10. Cancer Sci. 2011. PMID: 21231986 Free article.
766 results